Trial *
Publication Elamir YM, Bone (2021) (published paper)
Dates: 2020-09-01 to 2020-12-30
Funding: Not reported/unclear
Conflict of interest: No

Methods
RCT
Blinding: Unblinded
Location : Multicenter / USA
Follow-up duration (days): 30
Inclusion criteria
  • Hospitalized patients with COVID-19
Exclusion criteria
  • Admitted directly to the intensive care unit (ICU)
  • hypercalcemia and/or hyperphosphatemia on admission blood tests
  • untreated disorders of calcium metabolism including hyperparathyroidism, hypoparathyroidism, chronic renal insufficiency with glomerular filtration rate < 30 ml/min
  • prescribed calcitriol for any reason outside of the study.
Interventions
Treatment
Calcitriol
0.5 mcg once a day for 14 days or until discharge, whichever came first
Control
Standard care

Participants
Randomized
participants :
Calcitriol=25
Standard care=25
Characteristics of participants
N= 50
Mean age : NR
25 males
Severity : Mild: n=24 / Moderate: n=20 / Severe: n=6 Critical: n=0
Number of vaccinated participants: NR
Primary outcome
In the register
NR
In the report
Outcomes of the effectiveness of calcitriol in the treatment of COVID19 included oxygen requirements, length of hospital stay, need for ICU admission, mortality, and readmission.
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing willing stated in the publication:

Yes
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
Some concerns
General comment Only the published article was used in data extraction and assessment of risk of bias. No registry, protocol or statistical analysis plan was available.